Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2020-11, Vol.12 (11), p.3125
Hauptverfasser: Abeyakoon, Chathuri, van der Weyden, Carrie, Harrop, Sean, Khot, Amit, Dickinson, Michael, Yannakou, Costas K., Prince, H. Miles
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 11
container_start_page 3125
container_title Cancers
container_volume 12
creator Abeyakoon, Chathuri
van der Weyden, Carrie
Harrop, Sean
Khot, Amit
Dickinson, Michael
Yannakou, Costas K.
Prince, H. Miles
description Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.
doi_str_mv 10.3390/cancers12113125
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7692733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A645023504</galeid><sourcerecordid>A645023504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMoKtWz1wUvXtbmO81FkKJWKCp-nEOaTtvIbrImW6H_vdGKqHOZB-_HYx6D0AnB54xpPHQ2OEiZUEIYoWIHHVKsaC2l5ru_9AE6zvkVl2GMKKn20UERhEssD9HdY2ygiotqYqG1feyih9676qmHthpD01TPyYbcNTb0tvcxVD5UD5B8t4Jki1t_QdNN261ia4_Q3sI2GY6_9wC9XF89jyf19P7mdnw5rR3To76eMSuo0kJQKbjCc81hNifaYsGw5pKVRg6YINYpKoh2XM01pZRTKUcFlGyALra53XrWwtxB6Ms1pku-tWljovXmrxP8yizju1FSU8VYCTj7DkjxbQ25N63PrlSxAeI6G8qFGDGBFSno6RZd2gaMD4tYEt0nbi4lF5gWjBdquKVcijknWPwcQ7D5fJf59y72Acz-hd4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2455835071</pqid></control><display><type>article</type><title>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Abeyakoon, Chathuri ; van der Weyden, Carrie ; Harrop, Sean ; Khot, Amit ; Dickinson, Michael ; Yannakou, Costas K. ; Prince, H. Miles</creator><creatorcontrib>Abeyakoon, Chathuri ; van der Weyden, Carrie ; Harrop, Sean ; Khot, Amit ; Dickinson, Michael ; Yannakou, Costas K. ; Prince, H. Miles</creatorcontrib><description>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12113125</identifier><identifier>PMID: 33114606</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Care and treatment ; Hematopoietic stem cells ; Patient outcomes ; Review ; T cell lymphoma ; Transplantation</subject><ispartof>Cancers, 2020-11, Vol.12 (11), p.3125</ispartof><rights>COPYRIGHT 2020 MDPI AG</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</citedby><cites>FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</cites><orcidid>0000-0002-8848-9423 ; 0000-0002-0058-2448</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692733/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692733/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids></links><search><creatorcontrib>Abeyakoon, Chathuri</creatorcontrib><creatorcontrib>van der Weyden, Carrie</creatorcontrib><creatorcontrib>Harrop, Sean</creatorcontrib><creatorcontrib>Khot, Amit</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Yannakou, Costas K.</creatorcontrib><creatorcontrib>Prince, H. Miles</creatorcontrib><title>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</title><title>Cancers</title><description>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.</description><subject>Care and treatment</subject><subject>Hematopoietic stem cells</subject><subject>Patient outcomes</subject><subject>Review</subject><subject>T cell lymphoma</subject><subject>Transplantation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdkc1LAzEQxYMoKtWz1wUvXtbmO81FkKJWKCp-nEOaTtvIbrImW6H_vdGKqHOZB-_HYx6D0AnB54xpPHQ2OEiZUEIYoWIHHVKsaC2l5ru_9AE6zvkVl2GMKKn20UERhEssD9HdY2ygiotqYqG1feyih9676qmHthpD01TPyYbcNTb0tvcxVD5UD5B8t4Jki1t_QdNN261ia4_Q3sI2GY6_9wC9XF89jyf19P7mdnw5rR3To76eMSuo0kJQKbjCc81hNifaYsGw5pKVRg6YINYpKoh2XM01pZRTKUcFlGyALra53XrWwtxB6Ms1pku-tWljovXmrxP8yizju1FSU8VYCTj7DkjxbQ25N63PrlSxAeI6G8qFGDGBFSno6RZd2gaMD4tYEt0nbi4lF5gWjBdquKVcijknWPwcQ7D5fJf59y72Acz-hd4</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Abeyakoon, Chathuri</creator><creator>van der Weyden, Carrie</creator><creator>Harrop, Sean</creator><creator>Khot, Amit</creator><creator>Dickinson, Michael</creator><creator>Yannakou, Costas K.</creator><creator>Prince, H. Miles</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8848-9423</orcidid><orcidid>https://orcid.org/0000-0002-0058-2448</orcidid></search><sort><creationdate>20201101</creationdate><title>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</title><author>Abeyakoon, Chathuri ; van der Weyden, Carrie ; Harrop, Sean ; Khot, Amit ; Dickinson, Michael ; Yannakou, Costas K. ; Prince, H. Miles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-b3a527955265470d94ebd19a05309463211ce351ac72519c47d922242668bd163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Care and treatment</topic><topic>Hematopoietic stem cells</topic><topic>Patient outcomes</topic><topic>Review</topic><topic>T cell lymphoma</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abeyakoon, Chathuri</creatorcontrib><creatorcontrib>van der Weyden, Carrie</creatorcontrib><creatorcontrib>Harrop, Sean</creatorcontrib><creatorcontrib>Khot, Amit</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Yannakou, Costas K.</creatorcontrib><creatorcontrib>Prince, H. Miles</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abeyakoon, Chathuri</au><au>van der Weyden, Carrie</au><au>Harrop, Sean</au><au>Khot, Amit</au><au>Dickinson, Michael</au><au>Yannakou, Costas K.</au><au>Prince, H. Miles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma</atitle><jtitle>Cancers</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>12</volume><issue>11</issue><spage>3125</spage><pages>3125-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory “one-size-fits-all” approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field.</abstract><pub>MDPI AG</pub><pmid>33114606</pmid><doi>10.3390/cancers12113125</doi><orcidid>https://orcid.org/0000-0002-8848-9423</orcidid><orcidid>https://orcid.org/0000-0002-0058-2448</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2020-11, Vol.12 (11), p.3125
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7692733
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB Electronic Journals Library
subjects Care and treatment
Hematopoietic stem cells
Patient outcomes
Review
T cell lymphoma
Transplantation
title Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Haematopoietic%20Stem%20Cell%20Transplantation%20in%20Peripheral%20T-Cell%20Lymphoma&rft.jtitle=Cancers&rft.au=Abeyakoon,%20Chathuri&rft.date=2020-11-01&rft.volume=12&rft.issue=11&rft.spage=3125&rft.pages=3125-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12113125&rft_dat=%3Cgale_pubme%3EA645023504%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2455835071&rft_id=info:pmid/33114606&rft_galeid=A645023504&rfr_iscdi=true